Ranbaxy Receives Approval To Manufacture, Market Ran-Simvastatin In Canada

Ranbaxy has received final approval in Canada to manufacture and market Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (Simvastatin), from Health Canada, Therapeutic Products Directorate (TPD). Ran-Simvastatin tablets are for use as a lipid metabolism regulator.

Paul Drake, president of Ranbaxy Pharmaceuticals, said: “We look forward to marketing this organically developed product in all strengths that will be commercialized at an affordable price that will be beneficial to both the Canadian healthcare system, and most importantly, to Canadian patients.

Ran-Simvastatin represents the second approval granted to RPCI in July that will further expand the depth and breadth of our product portfolio of molecules that have clinical utility and value. We plan to launch Ran-Simvastatin in a September timeframe, he added.